Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (131-140 of 188) with videos related to

Pageof 19
Sort By:
British Journal of Cancer|January 21, 2021
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsNeil T Conlon, Jeffrey J Kooijman, Suzanne J C van Gerwen, et al.
Translational Oncology|August 27, 2024
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivoNeil T Conlon, Sandra Roche, Amira F Mahdi, et al.
Irish Journal of Medical Science|May 17, 2018
Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancerMegan Greally, Jennifer Kielty, Geoffrey A Watson, et al.
Journal of the National Cancer Institute|July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard, Michael Lind, Christopher Twelves, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
Breast Cancer Research and Treatment|November 3, 2012
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumoursBrigid C Browne, Alex J Eustace, Susan Kennedy, et al.
The Lancet. Oncology|December 7, 2019
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trialRobert Coleman, Dianne M Finkelstein, Carlos Barrios, et al.
Plos One|March 15, 2023
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancerSandra Roche, Patricia Gaule, Deirdre Winrow, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Therapeutic Advances in Medical Oncology|February 18, 2020
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancerAlexandra Canonici, Alacoque L Browne, Mohamed F K Ibrahim, et al.
Pageof 19

Showing results (131-140 of 188) with videos related to

Sort By:
Pageof 19
British Journal of Cancer|January 21, 2021
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsNeil T Conlon, Jeffrey J Kooijman, Suzanne J C van Gerwen, et al.
Translational Oncology|August 27, 2024
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivoNeil T Conlon, Sandra Roche, Amira F Mahdi, et al.
Irish Journal of Medical Science|May 17, 2018
Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancerMegan Greally, Jennifer Kielty, Geoffrey A Watson, et al.
Journal of the National Cancer Institute|July 22, 2004
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard, Michael Lind, Christopher Twelves, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
Breast Cancer Research and Treatment|November 3, 2012
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumoursBrigid C Browne, Alex J Eustace, Susan Kennedy, et al.
The Lancet. Oncology|December 7, 2019
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trialRobert Coleman, Dianne M Finkelstein, Carlos Barrios, et al.
Plos One|March 15, 2023
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancerSandra Roche, Patricia Gaule, Deirdre Winrow, et al.
Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.
Therapeutic Advances in Medical Oncology|February 18, 2020
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancerAlexandra Canonici, Alacoque L Browne, Mohamed F K Ibrahim, et al.
Pageof 19